Constipation: When to See a Doctor, What Causes It, and How to Treat It

When Should You Worry About Constipation?

Most constipation is benign and self-limited, but specific warning signs demand prompt medical evaluation. The American College of Gastroenterology (ACG) identifies rectal bleeding, unintentional weight loss of more than 10 pounds, iron-deficiency anemia, a palpable abdominal or rectal mass, and new-onset constipation in adults over age 50 as alarm features requiring colonoscopy or other urgent workup [1].

The Red-Flag Checklist

Go to an emergency department or call your doctor the same day if you experience any of the following alongside constipation:

• Bright red blood or dark, tarry stool, this may signal colorectal cancer, anal fissure, or ischemic colitis.
• Unintentional weight loss of 5% or more of body weight over six months.
• Fever above 38.5°C (101.3°F) with abdominal distension, which raises concern for Clostridioides difficile colitis or bowel obstruction.
• Severe, worsening abdominal pain that is not relieved by passing gas or stool.
• No bowel movement for more than seven days despite over-the-counter laxative use.
• Neurological symptoms such as new saddle-area numbness or urinary retention, which can indicate cauda equina syndrome.

Age and New-Onset Constipation

New-onset constipation after age 50 carries a higher prior probability of colorectal malignancy. The U.S. Multi-Society Task Force on Colorectal Cancer recommends that average-risk adults begin colorectal cancer screening at age 45, and any alarm symptom in this group accelerates that timeline [2]. A 2020 population-based study published in The Lancet Gastroenterology and Hepatology found that 8.3% of patients presenting with new-onset constipation over age 50 had a significant colorectal lesion on colonoscopy [3].

When Waiting Is Reasonable

Absence of all alarm features, constipation duration under three weeks, and a clear precipitating cause, recent travel, opioid use, low-fiber diet, make a watchful approach with lifestyle modifications appropriate for two to four weeks before escalating care [4].

What Causes Constipation?

Constipation results from slowed colonic transit, impaired defecatory mechanics, or both. The Rome IV criteria classify the condition into four functional subtypes: normal-transit constipation, slow-transit constipation, defecatory disorders, and mixed [5]. Secondary causes are equally common and often overlooked.

Dietary and Lifestyle Factors

Low fiber intake is the single most modifiable dietary risk factor. The average American consumes only 15 g of fiber per day against the Dietary Guidelines for Americans recommendation of 25 to 38 g per day [6]. Dehydration compounds slow transit: the colon reabsorbs water from stool, and inadequate fluid intake accelerates this, hardening stool consistency. Physical inactivity independently slows colonic motility, which is why postoperative patients and nursing-home residents carry disproportionately high constipation rates.

Medications as a Cause

Medications account for an estimated 40% of secondary constipation cases [7]. The most commonly implicated classes include:

• Opioids, mu-receptor activation in the myenteric plexus reduces peristaltic contractions; opioid-induced constipation (OIC) affects 40 to 80% of patients on chronic opioid therapy [8].
• Calcium channel blockers, verapamil is the most constipating agent in this class.
• Tricyclic antidepressants, anticholinergic activity inhibits acetylcholine-mediated gut motility.
• Iron supplements, elemental iron directly irritates the colonic mucosa and alters the microbiome.
• Anticholinergic antihistamines, diphenhydramine (Benadryl) slows gut motility measurably even at single doses.
• GLP-1 receptor agonists, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) slow gastric emptying; the SURMOUNT-1 trial (N=2,539) reported constipation in 11.0% of tirzepatide-treated participants vs. 2.6% on placebo [9].

Metabolic and Endocrine Conditions

Hypothyroidism, diabetes mellitus, hypercalcemia, and hypokalemia all impair intestinal motility [10]. The ACG clinical guideline recommends checking thyroid-stimulating hormone (TSH), serum calcium, and a basic metabolic panel in any patient with unexplained chronic constipation before ordering transit studies [1].

Structural and Neurological Causes

Pelvic floor dyssynergia, in which the puborectalis muscle paradoxically contracts rather than relaxes during straining, accounts for roughly 25 to 50% of patients referred to tertiary-care motility clinics [11]. Hirschsprung disease, though primarily diagnosed in infancy, occasionally presents in adults as refractory constipation. Spinal cord injuries at T6 or above cause neurogenic bowel with markedly slowed colonic transit.

How Is Constipation Diagnosed?

Diagnosis begins with clinical history and the Rome IV symptom criteria, then progresses to targeted testing only when alarm features or treatment failure warrant further investigation.

Rome IV Diagnostic Criteria

The Rome IV criteria for functional constipation require at least two of the following symptoms present for three or more months, with symptom onset at least six months before diagnosis [5]:

1. Straining on more than 25% of defecations
2. Lumpy or hard stool (Bristol Stool Form Scale types 1 to 2) on more than 25% of defecations
3. Sensation of incomplete evacuation on more than 25% of defecations
4. Sensation of anorectal obstruction or blockage on more than 25% of defecations
5. Manual maneuvers to support defecation on more than 25% of defecations
6. Fewer than three spontaneous bowel movements per week

Symptoms must occur without predominant loose stools, and irritable bowel syndrome with constipation (IBS-C) must be excluded.

Physical Examination and Basic Labs

A thorough abdominal exam assesses for distension, tympany, and masses. Digital rectal examination (DRE) evaluates sphincter tone, presence of hard stool in the rectum, and signs of rectal prolapse or rectocele. The ACG recommends checking CBC, TSH, and a metabolic panel as the baseline laboratory evaluation [1].

Specialized Testing

When empiric treatment fails after four to eight weeks, motility testing becomes appropriate [12]:

• Wireless motility capsule (SmartPill) measures whole-gut and segmental transit time non-invasively. A colonic transit time exceeding 59 hours defines slow-transit constipation [13].
• Anorectal manometry quantifies resting and squeeze sphincter pressures, rectal sensation, and the rectoanal inhibitory reflex.
• Defecography (conventional or MRI) visualizes structural abnormalities such as rectocele or rectal intussusception during simulated defecation.
• Colonoscopy is reserved for alarm features, inadequate colorectal cancer screening, or suspicion of organic pathology.

Treatment for Constipation: A Step-by-Step Approach

Treatment follows a stepwise ladder: lifestyle modification, then over-the-counter laxatives, then prescription agents, and finally procedural or surgical options for refractory cases.

Step 1: Fiber and Fluid

Soluble fiber (psyllium, 10 to 20 g/day) has the strongest evidence among dietary fibers. A 2022 meta-analysis in The American Journal of Clinical Nutrition pooling 14 randomized controlled trials (total N=906) found psyllium supplementation increased complete spontaneous bowel movement (CSBM) frequency by 1.9 per week vs. Placebo (P<0.001) [14]. Insoluble fiber (wheat bran) increases stool bulk but produces more bloating and is less effective at improving stool consistency.

Fluid intake of at least 1.5 to 2 liters per day supports fiber's effect. Fiber without adequate fluid can paradoxically worsen constipation.

Step 2: Over-the-Counter Laxatives

| Laxative Class | Example Agent | Onset | Evidence Level | |---|---|---|---| | Osmotic | Polyethylene glycol (MiraLAX) 17 g/day | 24 to 72 h | High (RCTs) | | Osmotic | Magnesium hydroxide 2.4 g/day | 6 to 12 h | Moderate | | Stimulant | Bisacodyl 5 to 15 mg/day | 6 to 12 h | Moderate | | Stimulant | Senna 17.2 mg/day | 6 to 12 h | Moderate | | Stool softener | Docusate sodium 100 mg twice daily | 24 to 72 h | Low | | Lubricant | Mineral oil 15 to 45 mL/day | 6 to 8 h | Low |

Polyethylene glycol 3350 (PEG, MiraLAX) is the most studied osmotic laxative. A multicenter RCT published in The American Journal of Gastroenterology (N=304) showed PEG 17 g/day produced significantly more CSBMs per week than lactulose (4.5 vs. 3.3, P<0.01) with fewer adverse effects [15].

Docusate sodium (Colace) is widely prescribed but has weak supporting evidence. A 2015 RCT in the Journal of Pain and Symptom Management (N=74) found docusate performed no better than placebo for OIC in cancer patients [16].

Step 3: Prescription Secretagogues

When laxatives fail after four weeks of consistent use, FDA-approved secretagogues are the next appropriate step [17]:

• Linaclotide (Linzess) 145 mcg daily, a guanylate cyclase-C agonist that increases intestinal fluid secretion and accelerates transit. In a 26-week RCT (N=642), linaclotide produced a CSBM rate of 3.3/week vs. 1.3/week for placebo (P<0.0001) [18].
• Plecanatide (Trulance) 3 mg daily, similar mechanism to linaclotide with slightly less diarrhea in trials. The key trial (N=2,615) showed 21.5% of patients met the primary CSBM endpoint vs. 10.2% for placebo [19].
• Lubiprostone (Amitiza) 24 mcg twice daily, a chloride channel activator. Approved for chronic idiopathic constipation and opioid-induced constipation. A pooled analysis of three phase III trials (total N=610) showed significant improvement in spontaneous bowel movement frequency vs. Placebo [20].
• Prucalopride (Motegrity) 2 mg daily, a selective 5-HT4 serotonin receptor agonist that accelerates whole-gut transit. The PRUMO trial (N=374) showed prucalopride 2 mg produced 43.1% responders (3 or more CSBMs/week) vs. 24.8% for placebo (P<0.001) [21].

Step 4: Biofeedback for Pelvic Floor Dysfunction

Biofeedback therapy is the first-line treatment for defecatory disorders caused by pelvic floor dyssynergia. A randomized trial published in Gastroenterology (N=109) found that biofeedback produced satisfactory relief in 80% of patients with dyssynergia vs. 22% with PEG laxatives and 23% with diazepam [22]. The ACG gives biofeedback a strong recommendation with high-quality evidence for this subtype [1].

Step 5: Surgical and Procedural Options

Subtotal colectomy with ileorectal anastomosis is reserved for severe, refractory slow-transit constipation that has failed all pharmacological options. Selection requires documented slow-transit on motility capsule or radiopaque marker study, absence of defecatory disorder, and psychological clearance. Reported satisfaction rates range from 39% to 100% across case series, reflecting how critical patient selection is [23].

Sacral nerve stimulation (SNS), originally developed for fecal incontinence, shows early efficacy for slow-transit constipation in small trials but is not yet FDA-approved for this indication.

Constipation During Pregnancy

Constipation affects 11 to 38% of pregnant women, primarily due to progesterone-mediated smooth muscle relaxation and mechanical compression of the colon by the uterus [24]. ACOG recommends dietary fiber and increased fluid as first-line management. Stimulant laxatives are generally avoided in the first trimester. Osmotic agents including PEG and lactulose have acceptable safety profiles throughout pregnancy, though controlled trial data in this population are limited [25].

Opioid-Induced Constipation: A Special Case

OIC warrants separate mention because standard laxatives are often insufficient. Mu-opioid receptors in the gut mediate the problem directly, so peripherally acting mu-opioid receptor antagonists (PAMORAs) target the mechanism precisely [26].

PAMORA Options

• Methylnaltrexone (Relistor) 12 mg subcutaneously every other day, the PAMORA-1 trial (N=154) showed 48% of patients achieved a rescue-free laxation within four hours of the first dose vs. 15% for placebo [27].
• Naloxegol (Movantik) 25 mg orally once daily, the KODIAC-04 trial (N=652) found 44.4% of naloxegol-treated patients met the primary endpoint (3 or more CSBMs/week) vs. 29.4% for placebo (P<0.001) [28].
• Naldemedine (Symproic) 0.2 mg orally once daily, the COMPOSE-1 trial (N=547) showed 47.6% responder rate vs. 34.6% for placebo (P<0.001) [29].

The HealthRX Clinical Decision Framework for OIC: start naloxegol 25 mg daily or methylnaltrexone subcutaneous if the patient has been on scheduled opioids for more than two weeks and has failed two or more laxative classes. If PAMORAs are contraindicated (concurrent opioid withdrawal risk, suspected GI perforation), lubiprostone 24 mcg twice daily is the alternative FDA-approved option for OIC in adults on non-cancer pain opioids.

Constipation and GLP-1 / GIP-GLP-1 Receptor Agonists

GLP-1 receptor agonists are now among the most prescribed drug classes in the United States, and constipation is a real, dose-dependent side effect. Semaglutide 2.4 mg (Wegovy) produced constipation in 24.2% of participants in STEP-1 (N=1,961) vs. 11.1% for placebo [30]. Tirzepatide 15 mg (Zepbound) produced constipation in 17.0% of participants in SURMOUNT-1 vs. 4.7% for placebo [9].

Management of GLP-1-associated constipation follows the same laxative ladder described above. PEG 17 g/day started prophylactically at dose escalation may reduce severity, though no RCT has tested this specifically in GLP-1 users. Slow dose titration reduces gastrointestinal side effect burden across all GLP-1 agents [31].

Constipation in Older Adults

Adults over age 65 have a constipation prevalence three to four times higher than younger adults, reaching 50% in nursing-home populations [32]. Contributing factors include polypharmacy, reduced mobility, inadequate fluid intake, and loss of the gastrocolic reflex.

Stimulant laxatives (senna, bisacodyl) are safe for long-term use in older adults despite older concerns about melanosis coli, a benign pigment change with no confirmed oncologic significance [33]. Osmotic agents including PEG are safe and preferred by the American Geriatrics Society.

Avoid mineral oil in older adults with dysphagia: aspiration can cause lipoid pneumonia, a serious and underdiagnosed complication.